Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.310 -0.010 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,395
Open 1.360
Bid (Size) 1.310 (800)
Ask (Size) 1.320 (400)
Prev. Close 1.320
Today's Range 1.310 - 1.360
52wk Range 1.168 - 1.960
Shares Outstanding 49,046,246
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
From MediciNova, Inc.
Via GlobeNewswire

Performance

YTD
-1.5%
-1.5%
1 Month
-7.1%
-7.1%
3 Month
+0.8%
+0.8%
6 Month
-15.5%
-15.5%
1 Year
-8.4%
-8.4%

More News

Read More
News headline image
MediciNova to Participate at the 38th Annual ROTH Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ ↗
Via Stocktwits
News headline image
2026 New Year’s Greetings from the CEO
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Message from the CEO to MediciNova Shareholders
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
From MediciNova, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Monday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
News headline image
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? ↗
Via Benzinga
News headline image
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Provides Shareholder Update on Key Developments
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From MediciNova, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is MediciNova, Inc. - Common Stock publicly traded?
Yes, MediciNova, Inc. - Common Stock is publicly traded.
What exchange does MediciNova, Inc. - Common Stock trade on?
MediciNova, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MediciNova, Inc. - Common Stock?
The ticker symbol for MediciNova, Inc. - Common Stock is MNOV on the Nasdaq Stock Market
What is the current price of MediciNova, Inc. - Common Stock?
The current price of MediciNova, Inc. - Common Stock is 1.310
When was MediciNova, Inc. - Common Stock last traded?
The last trade of MediciNova, Inc. - Common Stock was at 06/05/26 04:00 PM ET
What is the market capitalization of MediciNova, Inc. - Common Stock?
The market capitalization of MediciNova, Inc. - Common Stock is 64.25M
How many shares of MediciNova, Inc. - Common Stock are outstanding?
MediciNova, Inc. - Common Stock has 64M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.